

Anthera Pharmaceuticals Inc  
Form 4  
February 02, 2012

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
TRUEX PAUL F

(Last) (First) (Middle)

C/O ANTHERA  
PHARMACEUTICALS,  
INC., 25801 INDUSTRIAL BLVD  
SUITE B

(Street)

HAYWARD, CA 94538

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
Anthera Pharmaceuticals Inc  
[ANTH]

3. Date of Earliest Transaction  
(Month/Day/Year)  
01/27/2012

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)  
President and C.E.O.

6. Individual or Joint/Group Filing(Check  
Applicable Line)

☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common stock	01/27/2012		G <sup>(1)</sup>		7,000	D	\$ 0	620,125	I	By Trust
Common stock	01/31/2012		M		20,000	A	\$ 0.26	640,125	I	By Trust
Common stock								41,771	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (right to buy)	\$ 0.26	01/31/2011		M	20,000	(2) 01/23/2017	Common Stock	20,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TRUEX PAUL F C/O ANTHERA PHARMACEUTICALS, INC. 25801 INDUSTRIAL BLVD SUITE B HAYWARD, CA 94538	X		President and C.E.O.	

## Signatures

/S/ Paul F.  
Truex

02/03/2012

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On January 27, 2012, the reporting person transferred 7,000 shares to the 2006 Truex Irrevocable Trust U/A/D 04/06/2005

(2) 100% of the shares subject to this Stock Option were immediately exercisable. However, all unvested shares underlying this Stock Option were subject to a right of repurchase held by the Issuer, which lapsed according to the following vesting schedule: 25% of the total number of shares vest on the first anniversary of January 23, 2007 vesting start date (the "Vesting Start Date") and pro-rata monthly thereafter. This Stock Option has completely vested on the fourth anniversary of the Vesting Start Date.

**Remarks:**

Aggregate outstanding awards for the reporting person, both direct and indirect, total 1,329,838 common shares and common s

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.